Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.
2.

In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies.

Blumenthal RD, Hansen HJ, Goldenberg DM.

Br J Cancer. 2008 Sep 2;99(5):837-8; author reply 839-40. doi: 10.1038/sj.bjc.6604548. Epub 2008 Aug 12. No abstract available.

3.

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.

Radiat Res. 2007 Jul;168(1):65-71.

PMID:
17722994
4.

Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Blumenthal RD, Goldenberg DM.

Mol Biotechnol. 2007 Feb;35(2):185-97. Review.

PMID:
17435285
5.
6.

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.

Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM.

BMC Cancer. 2007 Jan 3;7:2.

7.
8.

An overview of chemosensitivity testing.

Blumenthal RD.

Methods Mol Med. 2005;110:3-18. Review.

PMID:
15901922
9.

Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.

Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM.

Cancer Immunol Immunother. 2005 Apr;54(4):315-27. Epub 2004 Dec 11.

PMID:
15592930
10.

Technology evaluation: cT84.66, City of Hope.

Blumenthal RD.

Curr Opin Mol Ther. 2004 Feb;6(1):90-5.

PMID:
15011786
11.

Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy.

Blumenthal RD, Leone E, Goldenberg DM.

Anticancer Res. 2003 Nov-Dec;23(6C):4613-9.

PMID:
14981904
12.

Technology evaluation: Onyvax-105, Onyvax.

Blumenthal RD.

Curr Opin Mol Ther. 2003 Dec;5(6):668-72.

PMID:
14755894
13.

An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.

Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D.

Int J Cancer. 2004 Jan 10;108(2):293-300.

14.

Unique molecular markers in human endometriosis: implications for diagnosis and therapy.

Blumenthal RD, Taylor A, Samoszuk M, Goldenberg DM.

Expert Rev Mol Med. 2001 Nov 20;3(26):1-12. doi: 10.1017/S1462399401003763.

PMID:
14585151
15.

Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materials.

O'Hara JA, Blumenthal RD, Grinberg OY, Grinberg S, Wilmot C, Goldenberg DM, Swartz HM.

Adv Exp Med Biol. 2003;530:205-14.

PMID:
14562718
16.

Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.

Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD.

Tumour Biol. 2003 Jan-Feb;24(1):32-9.

PMID:
12743424
17.
18.

Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.

Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD.

J Nucl Med. 2003 Jan;44(1):67-76.

19.

Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium.

Blumenthal RD, Taylor AP, Goldman L, Brown G, Goldenberg DM.

Fertil Steril. 2002 Dec;78(6):1294-300.

PMID:
12477527
20.

Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines.

Blumenthal RD, Reising A, Leon E, Goldenberg DM.

Clin Cancer Res. 2002 May;8(5):1301-9.

21.

Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.

Taylor AP, Osorio L, Craig R, Raleigh JA, Ying Z, Goldenberg DM, Blumenthal RD.

Clin Cancer Res. 2002 Apr;8(4):1213-22.

22.
23.

Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.

Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD.

Int J Oncol. 2002 Feb;20(2):379-84.

PMID:
11788905
24.

Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.

Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh JA, Papadopoulou M, Bloomer WD, Goldenberg DM.

Int J Cancer. 2001 Nov;94(4):564-71.

25.

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J.

Clin Cancer Res. 2001 Oct;7(10):3178-85.

26.

Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenografts.

O'Hara JA, Blumenthal RD, Grinberg OY, Demidenko E, Grinberg S, Wilmot CM, Taylor AM, Goldenberg DM, Swartz HM.

Radiat Res. 2001 Mar;155(3):466-73.

PMID:
11182798
27.

Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.

Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W, Goldenberg DM.

Clin Cancer Res. 2000 Dec;6(12):4900-7.

28.

Regulation of tumour drug delivery by blood flow chronobiology.

Blumenthal RD, Osorio L, Ochakovskaya R, Ying Z, Goldenberg DM.

Eur J Cancer. 2000 Sep;36(14):1876-84.

PMID:
10974637
29.

Degranulating eosinophils in human endometriosis.

Blumenthal RD, Samoszuk M, Taylor AP, Brown G, Alisauskas R, Goldenberg DM.

Am J Pathol. 2000 May;156(5):1581-8.

30.

Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy.

Blumenthal RD, Lew W, Reising A, Soyne D, Osorio L, Ying Z, Goldenberg DM.

Int J Cancer. 2000 Apr 15;86(2):276-80.

31.

Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.

Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM.

Cancer. 2000 Jan 15;88(2):333-43.

PMID:
10640965
32.

Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.

Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s.

PMID:
10541340
33.

Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.

Juweid ME, Blumenthal RD, Lew W, Hajjar G, Rubin AD, Goldenberg DM.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3337s-3342s.

PMID:
10541383
34.

Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.

Behr TM, Salib AL, Liersch T, Béhé M, Angerstein C, Blumenthal RD, Fayyazi A, Sharkey RM, Ringe B, Becker H, Wörmann B, Hiddemann W, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s.

PMID:
10541369
35.

Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.

Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.

J Nucl Med. 1999 Oct;40(10):1609-16.

37.
38.

Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.

Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W.

Int J Cancer. 1998 Aug 31;77(5):787-95.

39.

Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.

Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal RD, Goldenberg DM, Becker W.

Int J Cancer. 1998 May 29;76(5):738-48.

40.

Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies.

Juweid ME, Zhang CH, Blumenthal RD, Sharkey RM, Dunn R, Dunlop D, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2749-53.

PMID:
9406734
41.

Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?

Blumenthal RD, Alisauskas R, Juweid M, Sharkey RM, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2624-35.

PMID:
9406717
42.

Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2591-610.

PMID:
9406714
43.

Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.

Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.

Cancer Res. 1997 Dec 1;57(23):5309-19.

44.

Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.

Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM.

Int J Cancer. 1997 Jul 29;72(3):477-85.

45.

Application of cytokine intervention for improved radio-antibody dose delivery.

Blumenthal RD, Sharkey RM, Haywood L, Behr T, Goldenberg DM.

Int J Cancer. 1997 Jul 3;72(1):166-73.

46.

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.

Sharkey RM, Karacay H, Griffiths GL, Behr TM, Blumenthal RD, Mattes MJ, Hansen HJ, Goldenberg DM.

Bioconjug Chem. 1997 Jul-Aug;8(4):595-604.

PMID:
9258460
47.

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM.

Cancer Immunol Immunother. 1997 May;44(3):179-88.

PMID:
9191878
48.
49.

Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.

Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM.

Tumour Biol. 1997;18(6):367-77.

PMID:
9372870
50.

Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon.

Blumenthal RD, Stein R, Sharkey RM, Goldenberg DM, Ong GL, Klein KM, Mattes MJ.

Cancer Res. 1996 Aug 1;56(15):3508-15.

Supplemental Content

Loading ...
Support Center